FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898051648> ?p ?o ?g. }

• W2898051648 endingPage "e1861" @default.
• W2898051648 startingPage "e1861" @default.
• W2898051648 abstract "Connective tissue growth factor (CTGF) is a matricellular protein that plays a key role in wound healing and scar formation. Inhibition of CTGF by a specific antisense oligonucleotide significantly reduced scarring and fibrosis in animal models. This study examined whether an antisense oligonucleotide that inhibits human CTGF expression could reduce the severity of hypertrophic scar formation in patients following surgical revision of preexisting breast scars.This study was a 24-week multicenter, randomized, double-blind, within-subject, placebo-controlled phase 2b study evaluating the efficacy and safety of PF-06473871 in 2 regimens of either 3 or 4 intradermal injections (postsurgery weeks 2, 5, 8, and 11) of 5 mg/cm adjacent to the new surgical incision. One hundred subjects with bilateral hypertrophic scars resulting from prior breast surgery were randomized. Efficacy was determined by the Patient and Observer Scar Assessment Scale (POSAS).The Physician/Observer POSAS overall opinion score at (week 24) for the 4-injection regimen demonstrated a statistically significant (P = 0.022) treatment difference from placebo of 0.68, and the treatment difference for the 3-injection regimen was nonsignificant (P = 0.4). Physician evaluation of scar severity at (week 24) with the photo-guide in the 4-injection regimen had a significant reduction (point estimate of treatment difference of 0.43 favoring PF-06473871). The surgical effect was approximately 2.0 at week 24 and was nearly 3 times greater than the treatment effect. Patient evaluations using the POSAS and photo-guide were not significantly improved with either dose regimen. PF-06473871 was generally well tolerated systemically and locally.The 4-dose regimen of PF-06473871 provided statistically significant improvement, inhibiting severity of hypertrophic scar formation based on physician assessment. However, the effect of revision surgery alone is significant and may dominate the treatment effect of PF-06473871." @default.
• W2898051648 created "2018-10-26" @default.
• W2898051648 creator A5006219539 @default.
• W2898051648 creator A5022396568 @default.
• W2898051648 creator A5027281189 @default.
• W2898051648 creator A5046414584 @default.
• W2898051648 creator A5050486969 @default.
• W2898051648 creator A5054448346 @default.
• W2898051648 creator A5062798767 @default.
• W2898051648 creator A5072985008 @default.
• W2898051648 creator A5078740006 @default.
• W2898051648 creator A5082552742 @default.
• W2898051648 creator A5084824434 @default.
• W2898051648 date "2018-09-01" @default.
• W2898051648 modified "2023-10-16" @default.
• W2898051648 title "A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring" @default.
• W2898051648 cites W1606096607 @default.
• W2898051648 cites W1798749130 @default.
• W2898051648 cites W1996562151 @default.
• W2898051648 cites W2011196230 @default.
• W2898051648 cites W2053688285 @default.
• W2898051648 cites W2112500666 @default.
• W2898051648 cites W2116323280 @default.
• W2898051648 cites W2128629246 @default.
• W2898051648 cites W2184184250 @default.
• W2898051648 cites W2883920716 @default.
• W2898051648 doi "https://doi.org/10.1097/gox.0000000000001861" @default.
• W2898051648 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6191237" @default.
• W2898051648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30349773" @default.
• W2898051648 hasPublicationYear "2018" @default.
• W2898051648 type Work @default.
• W2898051648 sameAs 2898051648 @default.
• W2898051648 citedByCount "10" @default.
• W2898051648 countsByYear W28980516482020 @default.
• W2898051648 countsByYear W28980516482021 @default.
• W2898051648 countsByYear W28980516482022 @default.
• W2898051648 crossrefType "journal-article" @default.
• W2898051648 hasAuthorship W2898051648A5006219539 @default.
• W2898051648 hasAuthorship W2898051648A5022396568 @default.
• W2898051648 hasAuthorship W2898051648A5027281189 @default.
• W2898051648 hasAuthorship W2898051648A5046414584 @default.
• W2898051648 hasAuthorship W2898051648A5050486969 @default.
• W2898051648 hasAuthorship W2898051648A5054448346 @default.
• W2898051648 hasAuthorship W2898051648A5062798767 @default.
• W2898051648 hasAuthorship W2898051648A5072985008 @default.
• W2898051648 hasAuthorship W2898051648A5078740006 @default.
• W2898051648 hasAuthorship W2898051648A5082552742 @default.
• W2898051648 hasAuthorship W2898051648A5084824434 @default.
• W2898051648 hasBestOaLocation W28980516481 @default.
• W2898051648 hasConcept C126322002 @default.
• W2898051648 hasConcept C126894567 @default.
• W2898051648 hasConcept C141071460 @default.
• W2898051648 hasConcept C142724271 @default.
• W2898051648 hasConcept C170493617 @default.
• W2898051648 hasConcept C204787440 @default.
• W2898051648 hasConcept C27081682 @default.
• W2898051648 hasConcept C2775960820 @default.
• W2898051648 hasConcept C2777642821 @default.
• W2898051648 hasConcept C2778698245 @default.
• W2898051648 hasConcept C2780559512 @default.
• W2898051648 hasConcept C2780631158 @default.
• W2898051648 hasConcept C2781413609 @default.
• W2898051648 hasConcept C518705261 @default.
• W2898051648 hasConcept C71924100 @default.
• W2898051648 hasConceptScore W2898051648C126322002 @default.
• W2898051648 hasConceptScore W2898051648C126894567 @default.
• W2898051648 hasConceptScore W2898051648C141071460 @default.
• W2898051648 hasConceptScore W2898051648C142724271 @default.
• W2898051648 hasConceptScore W2898051648C170493617 @default.
• W2898051648 hasConceptScore W2898051648C204787440 @default.
• W2898051648 hasConceptScore W2898051648C27081682 @default.
• W2898051648 hasConceptScore W2898051648C2775960820 @default.
• W2898051648 hasConceptScore W2898051648C2777642821 @default.
• W2898051648 hasConceptScore W2898051648C2778698245 @default.
• W2898051648 hasConceptScore W2898051648C2780559512 @default.
• W2898051648 hasConceptScore W2898051648C2780631158 @default.
• W2898051648 hasConceptScore W2898051648C2781413609 @default.
• W2898051648 hasConceptScore W2898051648C518705261 @default.
• W2898051648 hasConceptScore W2898051648C71924100 @default.
• W2898051648 hasIssue "9" @default.
• W2898051648 hasLocation W28980516481 @default.
• W2898051648 hasLocation W28980516482 @default.
• W2898051648 hasLocation W28980516483 @default.
• W2898051648 hasLocation W28980516484 @default.
• W2898051648 hasLocation W28980516485 @default.
• W2898051648 hasOpenAccess W2898051648 @default.
• W2898051648 hasPrimaryLocation W28980516481 @default.
• W2898051648 hasRelatedWork W1798749130 @default.
• W2898051648 hasRelatedWork W2048544033 @default.
• W2898051648 hasRelatedWork W2053688285 @default.
• W2898051648 hasRelatedWork W2087027548 @default.
• W2898051648 hasRelatedWork W2089740159 @default.
• W2898051648 hasRelatedWork W2364760470 @default.
• W2898051648 hasRelatedWork W2372473182 @default.
• W2898051648 hasRelatedWork W2386791695 @default.
• W2898051648 hasRelatedWork W2391253676 @default.
• W2898051648 hasRelatedWork W3150099085 @default.
• W2898051648 hasVolume "6" @default.

• next